No Prescription |
 |
 | ||
|
Vallergan Forte Syrup Generic Trimeprazine Tartarate |
|
| ||
No Prescription » Prescription Drugs 16 » Vallergan Forte Syrup Generic Trimeprazine Tartarate IndicationsVallergan Forte is used in:Urticaria and pruritus. Premedication for anaesthesia. Dosage and AdministrationVallergan Forte is not recommended for infants less than two years of age.Urticaria and PruritusAdults10 mg two or three times daily. Up to 100 mg per day has been used in intractable cases.ElderlyDosage should be reduced to 10 mg once or twice daily.Children2.5 to 5 mg three or four times daily.Pre-anaesthetic MedicationChildren (2 to 7 years of age)The maximum dosage of Vallergan Forte syrup recommended for this indication is 2 mg/kg bodyweight. Buy Vallergan Forte Syrup Generic Trimeprazine Tartarate and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Vallergan Forte Syrup Generic Trimeprazine Tartarate: Product Type: Prescription Drugs 16 Vallergan Forte Syrup ( Generic Trimeprazine Tartarate ) Vallergan Forte Syrup (Generic Trimeprazine Tartarate) Generic Trimeprazine Tartarate 30mg/5mL Generic Trimeprazine Tartarate Vallergan Forte Syrup
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
